Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technological platforms boost European cardiovascular research

13.12.2006
Proteomics, bioinformatics and Zebrafish are the novel tools set up by the European Vascular Genomics Network (EVGN).

Advanced technology is crucial to today’s biomedical research. But it is expensive and it requires specific expertise, which is expensive too. Then sharing becomes a must. And it guarantees a high level of cooperation among research groups throughout Europe. In 2006, the European Vascular Genomics Network (EVGN), a Network of Excellence funded by the European Union within its 6th Framework Programme, has launched three platforms, all of them representing cutting edge tools in the field of cardiovascular science and aimed at strengthening and improving the research effectiveness of the Network. The platforms were presented during the Third EVGN annual Conference (Toulouse, 11-14 December 2006).

The Zebrafish platform (Zebrafish, the fish Danio rerio, is an extremely versatile model organism in modern molecular biology) intends to provide EVGN scientists with a direct access to the Zebrafish model system for in vivo studies of cardiovascular development and disease. The Zebrafish platform is based at IFOM, the FIRC Institute of Molecular Oncology (Milan, Italy) and it is led by EVGN scientist Marina Mione.

The bioinformatics platform will provide EVGN researchers with a comprehensive set of software and web tools for storing, accessing, analyzing and elaborating the huge amount of data that comes from today’s high throughput technologies (in particular, gene and protein expression data). The platform is managed by Anton Horrevoets of the Academisch Medisch Centrum (University of Amsterdam).

Last but not least, an innovative proteomic platform has been launched, to perform advanced studies on structure and function of the proteins involved in the process of formation and development of cardiovascular disease. The promise of proteomics in this field is to carry out large scale-studies of gene expression at the protein level, providing the basis for a detailed understanding of pathophysiological mechanisms and leading to the discovery of potential targets for drug development. The EVGN proteomic platform is managed by Manuel Mayr, of the St George's Hospital Medical School (London, UK).

“EVGN platforms – explains EVGN scientific coordinator Alain Tedgui, of Inserm, Paris – represent essential tools to our network. These technologies are necessary for today’s research, but they are extremely expensive, and would not be affordable for individual institutes. Also, every platform requires specific and advanced expertise, and this is expensive too. Sharing human and technological resources becomes then crucial. Also, having common platforms guarantees that we all work with experts with both highly specific expertise and a solid background in cardiovascular disease.” More than being just core facilities, the EVGN platforms base their work on collaborative projects. “The scientists who work at the platforms – adds Tedgui – are not technicians, they are indeed involved in collaborative projects with several EVGN partners.”

The future of EVGN

EVGN, which was launched in 2004, will be active until the end of 2008. But its legacy will be taken on by new specific projects to be activated during the 7th Framework Programme. “What we have done here, with EVGN, was to lay the foundations of European vascular disease with a highly collaborative approach. Now we need to go on. Some of the area that will be covered by the new Programme – says Tedgui – will directly interest EVGN members. For example inflammatory and vascular remodelling, or stem cells in ischemic disease. Several groups and leaders of EVGN will join together and propose innovative actions in these fields of research.”

The European Vascular Genomics Network (EVGN) is the first Network of excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).

The Third EVGN Annual Conference is supported by an unrestricted educational grant from Laboratoires SERVIER.

Francesca Noceti | alfa
Further information:
http://www.ifom-ieo-campus.it
http://www.evgn.org

Further reports about: Cardiovascular EVGN expensive vascular disease

More articles from Life Sciences:

nachricht Seeing on the Quick: New Insights into Active Vision in the Brain
15.08.2018 | Eberhard Karls Universität Tübingen

nachricht New Approach to Treating Chronic Itch
15.08.2018 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Unraveling the nature of 'whistlers' from space in the lab

15.08.2018 | Physics and Astronomy

Diving robots find Antarctic winter seas exhale surprising amounts of carbon dioxide

15.08.2018 | Earth Sciences

Early opaque universe linked to galaxy scarcity

15.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>